$DTHR Upcoming milestones for 2018 include:
Post# of 21196
First Product Launch: Dthera plans to launch its lead product, ReminX, an artificial-intelligence-powered consumer health product designed to deliver reminiscence therapy digitally to individuals suffering from dementia from Alzheimer's disease and other neurodegenerative conditions, as well as for seniors experiencing social isolation.
The product is comprised of a proprietary software tablet, specifically designed to be robust and user-friendly to this user group, and an Artificial Intelligence chatbot called Rachel that streamlines and simplifies the process of putting content onto the platform.
The tablet sits in a charging docking station, does not have any buttons or cords to confuse or frustrate the users and automatically plays ReminX content when picked up.
The Rachel, guides family members/caregivers to upload optimal content and organizing it into an effective narrative primarily via text message. Rachel "asks" group members to add photos, videos, and audio. Proprietary emotional recognition software in the tablet provides feedback as to which content is most helpful, allowing Rachel to "learn" what works best and inform family members.
In addition to text messaging, the ReminX product has several additional channels of content collection. These include The ReminX Family Mobile App (iOS/Android), The ReminX Family Web App, and email.
ReminX will be sold on a subscription basis for $40 a month. The Company anticipates that the primary purchasers will be adult children of the elderly suffering from cognitive decline or social isolation.
https://finance.yahoo.com/news/uipath-set-hos...00309.html